DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Vitamin D for Chemoprevention

Phase 1

Completed

Conditions: Hypertension
Prostate Cancer
Gastrointestinal Cancers

Interventions: Drug: Vitamin D
Dietary Supplement: Placebo

First Posted Date: 2008-01-03

Last Posted Date: 2015-04-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 328

Registration Number: NCT00585637

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2007-12-21

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00578149

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Phase 2

Completed

Conditions: Mucosal Lentiginous Melanoma
Acral Lentiginous Malignant Melanoma

Interventions: Drug: Sunitinib

First Posted Date: 2007-12-20

Last Posted Date: 2016-12-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 52

Registration Number: NCT00577382

Locations: 🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 1

Completed

Conditions: Pancreatic Neuroendocrine Tumor

Interventions: Drug: RAD001
Drug: Temozolomide

First Posted Date: 2007-12-19

Last Posted Date: 2020-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT00576680

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Simvastatin in Waldenstrom's Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Simvastatin

First Posted Date: 2007-12-18

Last Posted Date: 2015-12-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00575965

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Adenosquamous Cell Carcinoma
Basaloid Squamous Cell Carcinoma
Undifferentiated Carcinoma

Interventions: Drug: Abraxane
Drug: Erbitux
Drug: Carboplatin
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2007-12-11

Last Posted Date: 2017-11-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00570674

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Graft-vs-Host Disease

Interventions: Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: Bortezomib

First Posted Date: 2007-10-24

Last Posted Date: 2014-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00548717

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Active After Cancer Trial (AACT)

Not Applicable

Active, not recruiting

Conditions: Breast Cancer
Colorectal Cancer

Interventions: Behavioral: Telephone-Based exercise intervention

First Posted Date: 2007-10-23

Last Posted Date: 2024-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 120

Registration Number: NCT00548236

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Phase 2

Completed

Conditions: Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Vaginal Cancer
Carcinoma of the Vulva

Interventions: Drug: Avastin

First Posted Date: 2007-10-17

Last Posted Date: 2017-03-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00545792

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2007-10-12

Last Posted Date: 2016-05-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00543114

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy